ArticlePloS one2026
Modulation of angiogenic transcription factor ERG via miR-6756 and miR-3190.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiogenesis plays a crucial role in cancer metastasis as tumors need to establish an increased blood supply to satisfy the demand for oxygen and nutrients. Numerous genes regulate this process, and various mechanisms including microRNAs regulate the expression of these genes. In the current study, we hypothesized that miR-6756 and miR-3190 regulate angiogenic mediators such as transcription factor ETS-related gene (ERG). Detailed bioinformatics analyses were performed to locate binding sites of miR-6756 and miR-3190 on ERG mRNA. miR-6756 and miR-3190 were cloned and overexpressed in primary endothelial cells to analyze ERG expression. To evaluate ERG activity reporter assays were performed in response to miR-6756 and miR-3190 over-expression. The effects of miRs on angiogenesis were measured by cell migration rate using the scratch assay. The expression of angiogenic targets of ERG was analyzed through qPCR with and without miR-6756 and miR-3190 overexpression. Lastly, VE-cadherin; an endothelial-specific ERG target was analyzed after miRs overexpression. Bioinformatics analyses showed that both miR-6756 and miR-3190 each have three binding sites on the mRNA of ERG. ERG expression at both mRNA (p < 0.001) and the protein level (p < 0.001) was significantly reduced after miR-6756 and miR-3190 overexpression. Also, the transcriptional activity of ERG significantly reduced (p < 0.05) in response to miRs overexpression. Cell migration rate (p < 0.001) and ERG angiogenic target genes were also decreased significantly (p < 0.001). VE-cadherin also showed significantly reduced expression and activity after miR-6756 and miR-3190 over-expression. This study indicates that miR-6756 and miR-3190 can regulate ERG expression and its target genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.